These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 21925000)

  • 1. Rituximab and its use in autoimmune bullous disorders.
    Daniel BS; Murrell DF; Joly P
    Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and its use in autoimmune bullous disorders.
    Daniel BS; Murrell DF; Joly P
    Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for autoimmune blistering diseases: recent studies, new insights.
    Lunardon L; Payne AS
    G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of bullous systemic lupus erythematosus.
    Alsanafi S; Kovarik C; Mermelstein AL; Werth VP
    J Clin Rheumatol; 2011 Apr; 17(3):142-4. PubMed ID: 21441817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
    Li Y; Foshee JB; Sontheimer RD
    J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
    Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
    J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab.
    Jensen AØ; Møller BK; Vangkilde A; Mark B; Obitz ER; Kragballe K; Iversen L
    Br J Dermatol; 2009 Jun; 160(6):1359-61. PubMed ID: 19416252
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
    Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
    Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
    Shetty S; Ahmed AR
    Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Off-label use of biological therapies in systemic diseases].
    Hachulla E
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
    [No Abstract]   [Full Text] [Related]  

  • 16. An antibody treats almost all refractory autoimmune diseases: fact and beyond.
    Lin LY; Hsu MH; Yang KD
    J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
    Kasperkiewicz M; Zillikens D
    Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.